4th Quarter - Report

SUMMIT PUBLIC AFFAIRS for VANDA PHARMACEUTICALS INC.

Firm
Client
Income
$40,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Issues affecting the pharmaceutical industry, including the prescription drug approval process, animal testing, and gastroparesis issues. COVID-19 clinical trials. H.R. 7608, Agriculture, Rural Development, FDA, and Related Agencies Appropriations for FY2021, provisions regarding FDA testing for new drug applications. H.R. 133, Consolidated Appropriations Act, 2021, provisions related to federal response to COVID-19 pandemic.

LobbyistCovered position, as disclosed
CICELY SIMPSON —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 7608 (116th), H.R. 133 (116th)

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details. Other amounts

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.